A detailed history of Norden Group LLC transactions in Biogen Inc. stock. As of the latest transaction made, Norden Group LLC holds 1,027 shares of BIIB stock, worth $195,951. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,027
Previous 1,440 28.68%
Holding current value
$195,951
Previous $311 Million 23.33%
% of portfolio
0.05%
Previous 0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

SELL
$190.52 - $236.72 $78,684 - $97,765
-413 Reduced 28.68%
1,027 $238 Million
Q1 2024

Apr 30, 2024

SELL
$212.02 - $267.71 $5.51 Million - $6.96 Million
-25,996 Reduced 94.75%
1,440 $311 Million
Q1 2024

Apr 19, 2024

BUY
$212.02 - $267.71 $5.57 Million - $7.04 Million
26,286 Added 2285.74%
27,436 $5.92 Billion
Q4 2023

Feb 05, 2024

SELL
$222.59 - $267.94 $221,699 - $266,868
-996 Reduced 46.41%
1,150 $298 Million
Q3 2023

Nov 06, 2023

BUY
$253.3 - $285.89 $543,581 - $613,519
2,146 New
2,146 $552 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $27.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Norden Group LLC Portfolio

Follow Norden Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norden Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Norden Group LLC with notifications on news.